Journal of travel medicine
-
Acute encephalitis syndrome (AES) is a major public health concern in India, and the Japanese Encephalitis (JE) virus is the most common cause of viral encephalitis in Asia affecting children under the age of 15 years. In India, despite the introduction of the JE vaccine (SA-14-14-2) in the immunization programme, JE continues to account for 15-20% of AES cases to date. This study evaluates the immunogenicity of live attenuated SA-14-14-2 JE vaccine in terms of persistence of the humoral response after two doses. ⋯ The study showed a decreasing trend of anti-JEV specific IgG antibody titres across the five groups based on the duration following two doses of SA-14-14-2 vaccine. The results emphasize the significance of booster doses of vaccine for children living in endemic areas.
-
Clinical Trial
Immunogenicity of a single fractional intradermal dose of Japanese encephalitis live attenuated chimeric vaccine.
Japanese encephalitis (JE) is endemic in Asia and the western Pacific. Vaccination is recommended for travellers to endemic regions, but the high cost of the vaccine is a major barrier to uptake. ⋯ ACTRN12621000024842.
-
In response to the vaccine shortage of yellow fever vaccine (YF-VAX) due to manufacturing delays, the unapproved 17D-204 YF-VAX was used as an investigator-initiated clinical trial in Japan. The vaccine was administered to 11 279 participants in 19 YF vaccination centres in Japan, and few serious adverse events were observed.